Clinical Trial: Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomize

Brief Summary: This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature associated with low IGF-1 levels but who produce sufficient growth hormone (GH). Subjects will be randomized to either an observation arm or to active treatment.

Detailed Summary:

Prepubertal growth failure associated with primary IGF-1 deficiency (IGFD). Primary IGFD is a term that has been used to describe patients with intrinsic cellular defects in GH action. In this protocol, primary IGFD is defined as short stature (height standard deviation score[SDS]<-2 below the mean for age and gender), low serum IGF-1 (IGF-1 SDS <-2 below the mean for age and gender), and levels of growth hormone (GH) that are normal (≥7ng/mL) after a GH stimulation test. Primary IGFD is believed to result from a lower than normal ability to produce IGF-1 when exposed to normal levels of GH, i.e., a type of GH insensitivity or GH resistance.

This trial is one year, randomized, open label, observation-controlled, parallel-dose comparison efficacy and safety study conducted in approximately 40 centers across the United States.


Sponsor: Ipsen

Current Primary Outcome: Height Velocity During the First Year - Intent to Treat (ITT)Population [ Time Frame: Measured at baseline and at one year ]

Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement.


Original Primary Outcome:

  • Change in height standard deviation (SD) score over 1 year
  • Change in height velocity from the pretreatment height velocity over 1 year


Current Secondary Outcome:

  • Change From Baseline in Height Standard Deviation (SD) Score at One Year - ITT Population [ Time Frame: Measured at baseline and at one year ]
    Height to be measured standing without shoes as the average of three measurements by the same observer using identical technique with a Harpenden or other wall mounted stadiometer. Reposition subject between each measurement. Please note that Standard Deviation (SD) Score is a term used in growth studies. The SD Score is calculated as the patient value minus the mean divided by the standard deviation. The mean and the standard deviation vary depending on the age and sex of the child.
  • Changes in Bone Age From Baseline to One Year [ Time Frame: Measured at baseline and at one year ]
    Plain X-rays of the left hand and wrist exposed for bone age appraisal. The films are sent to a central facility for standardized evaluation.
  • Percent Changes From Baseline in Serum Concentrations of IGF-1 at One Year [ Time Frame: Measured at baseline and at one year ]
    Blood sample was collected while subject is in a fasting state for measuring the level of IGF-1 in the growth factor panel.
  • Percent Changes From Baseline in Serum Concentrations of IGF-2 at One Year [ Time Frame: Measured at baseline and at one year ]
    Blood sample was collected for measuring the level of IGF-2 in the growth factor panel.
  • Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) at One Year [ Time Frame: Measured at baseline and at one year ]
    Blood sample was collected for measuring the level of insulin-like growth factor binding protein-2 (IGFBP-2) in the growth factor panel.
  • Percent Changes From Baseline in Serum Concentrations of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) at One Year [ Time Frame: Measured at baseline and at one year ]
    Blood sample was collected while subject is in a fasting state for measuring the level of IGFBP-3 in the growth factor panel.
  • IGF Generation Test: Change of Serum IGF-1 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH) [ Time Frame: Study Day 1 and Day 7 ]
    Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.
  • IGF Generation Test: Change of Serum IGFBP-3 After 7 Days Exposure to Recombinant Human Growth Hormone (rhGH) [ Time Frame: Study Day 1 and Day 7 ]
    Blood drawn at Study Day 1, followed by 7 days of rhGH daily dosing at 0.05 mg/kg of body weight. Additional blood draw at Study Day 7.


Original Secondary Outcome:

  • Changes in serum concentrations of IGF-1, IGF-2, insulin-like growth factor binding protein-2 (IGFBP-2) and insulin-like growth factor binding protein-3 (IGFBP-3) during the course of the study
  • Changes in bone age over one year
  • IGF generation test: serum IGF-1 and IGFBP-3 changes after 7 days exposure to recombinant human growth hormone (rhGH)


Information By: Ipsen

Dates:
Date Received: July 27, 2005
Date Started: March 2004
Date Completion:
Last Updated: June 14, 2012
Last Verified: June 2012